369 research outputs found
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice
No full textBackground: Tetrahydrocannabinol:cannabidiol (THC:CBD) oromucosal spray (Sativex®) is an add-on therapy for moderate-to-severe multiple sclerosis (MS)-related drug-resistant spasticity (MSS). Aim: The MOVE-2 EU study collected data from everyday clinical practice concerning the effectiveness and tolerability of THC:CBD. Methods: This was an observational, prospective, multicentre, non-interventional study. Patients with resistant MSS prescribed add-on THC:CBD oromucosal spray according to approved labelling, were followed for 3 months. After 1 month, only responders (≥20% improvement in spasticity) continued treatment. The main endpoints were the evolution of MSS and associated symptoms, quality of life (QoL) and tolerability. Results: Four hundred and thirty three patients (55% female) were recruited (98% in Italy). The mean duration of MSS was 7.4 years and baclofen was used by 78.1% of participants. Three hundred and forty nine participants continued with THC:CBD oromucosal spray after 1 month, and 281 after 3 months. THC:CBD mean dosage was 6 sprays/day. MSS scores and spasticity-related symptoms (spasms, fatigue, pain, sleep quality and bladder dysfunction) were significantly improved by THC:CBD at 3 months, as were activities of daily living, and QoL (EQ-5D VAS). Adverse events, none of which were severe or serious, were reported by 10.4% of patients. Conclusions: In everyday clinical practice, THC:CBD oromucosal spray provided symptomatic relief of MSS and related troublesome symptoms
sj-DOC-1-tan-10.1177_17562864211058298 – Supplemental material for Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
No full textSupplemental material, sj-DOC-1-tan-10.1177_17562864211058298 for Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice by Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H. Hua, Celia Oreja-Guevara, Daniel Selchen, Per Soelberg Sørensen, Patrick Vermersch, Heinz Wiendl, Hashem Salloukh and Bassem Yamout in Therapeutic Advances in Neurological Disorders</p
Supplementary Material, MSJ771875_supplementary_material – Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
No full textSupplementary Material, MSJ771875_supplementary_material for Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study by Gavin Giovannoni, Per Soelberg Sorensen, Stuart Cook, Kottil W Rammohan, Peter Rieckmann, Giancarlo Comi, Fernando Dangond, Christine Hicking and Patrick Vermersch in Multiple Sclerosis Journal</p
Diagnosis and treatment of progressive multiple sclerosis: A position paper
No full textBackground and purpose: Multiple sclerosis (MS) is an unpredictable disease characterised by a highly variable disease onset and clinical course. Three main clinical phenotypes have been described. However, distinguishing between the two progressive forms of MS can be challenging for clinicians. This article examines how the diagnostic definitions of progressive MS impact clinical research, the design of clinical trials and, ultimately, treatment decisions. Methods: We carried out an extensive review of the literature highlighting differences in the definition of progressive forms of MS, and the importance of assessing the extent of the ongoing inflammatory component in MS when making treatment decisions. Results: Inconsistent results in phase III clinical studies of treatments for progressive MS, may be attributable to differences in patient characteristics (e.g., age, clinical and radiological activity at baseline) and endpoint definitions. In both primary and secondary progressive MS, patients who are younger and have more active disease will derive the greatest benefit from the available treatments. Conclusions: We recommend making treatment decisions based on the individual patient's pattern of disease progression, as well as functional, clinical and imaging parameters, rather than on their clinical phenotype. Because the definition of progressive MS differs across clinical studies, careful selection of eligibility criteria and study endpoints is needed for future studies in patients with progressive MS
sj-docx-2-dhj-10.1177_20552076231173531 - Supplemental material for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
No full textSupplemental material, sj-docx-2-dhj-10.1177_20552076231173531 for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis by Gavin Giovannoni, Enrique Alvarez, Ellen Tutton, Olaf Hoffmann, Yan Xu, Patrick Vermersch, Celia Oreja-Guevara, Maria Trojano, Ralf Gold, René Robles-Cedeño, Mudeer Khwaja, Bianca Stadler, Jo Vandercappellen and Tjalf Ziemssen in DIGITAL HEALTH</p
sj-docx-1-dhj-10.1177_20552076231173531 - Supplemental material for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
No full textSupplemental material, sj-docx-1-dhj-10.1177_20552076231173531 for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis by Gavin Giovannoni, Enrique Alvarez, Ellen Tutton, Olaf Hoffmann, Yan Xu, Patrick Vermersch, Celia Oreja-Guevara, Maria Trojano, Ralf Gold, René Robles-Cedeño, Mudeer Khwaja, Bianca Stadler, Jo Vandercappellen and Tjalf Ziemssen in DIGITAL HEALTH</p
sj-png-4-dhj-10.1177_20552076231173531 - Supplemental material for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
No full textSupplemental material, sj-png-4-dhj-10.1177_20552076231173531 for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis by Gavin Giovannoni, Enrique Alvarez, Ellen Tutton, Olaf Hoffmann, Yan Xu, Patrick Vermersch, Celia Oreja-Guevara, Maria Trojano, Ralf Gold, René Robles-Cedeño, Mudeer Khwaja, Bianca Stadler, Jo Vandercappellen and Tjalf Ziemssen in DIGITAL HEALTH</p
sj-png-3-dhj-10.1177_20552076231173531 - Supplemental material for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
No full textSupplemental material, sj-png-3-dhj-10.1177_20552076231173531 for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis by Gavin Giovannoni, Enrique Alvarez, Ellen Tutton, Olaf Hoffmann, Yan Xu, Patrick Vermersch, Celia Oreja-Guevara, Maria Trojano, Ralf Gold, René Robles-Cedeño, Mudeer Khwaja, Bianca Stadler, Jo Vandercappellen and Tjalf Ziemssen in DIGITAL HEALTH</p
sj-docx-1-mso-10.1177_20552173231203816 - Supplemental material for Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
No full textSupplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis by John Kramer, Ralf Linker, David Paling, Adam Czaplinski, Olaf Hoffmann, V Wee Yong, Noreen Barker, Amy Perrin Ross, Elisabeth Lucassen, Mohammad Gufran, Xixi Hu, Ronald Zielman, Gustavo Seifer and Patrick Vermersch in Multiple Sclerosis Journal – Experimental, Translational and Clinical</p
sj-docx-6-dhj-10.1177_20552076231173531 - Supplemental material for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
No full textSupplemental material, sj-docx-6-dhj-10.1177_20552076231173531 for Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis by Gavin Giovannoni, Enrique Alvarez, Ellen Tutton, Olaf Hoffmann, Yan Xu, Patrick Vermersch, Celia Oreja-Guevara, Maria Trojano, Ralf Gold, René Robles-Cedeño, Mudeer Khwaja, Bianca Stadler, Jo Vandercappellen and Tjalf Ziemssen in DIGITAL HEALTH</p
- …
